Kopran Limited, a prominent pharmaceutical company, has announced a significant development in its corporate structure. The co-promoters of the company have finalized a family agreement aimed at strengthening the management control of the organization.

Key Details of the Agreement

According to the disclosure made to the stock exchanges, the promoters of Kopran Limited have executed a Memorandum of Family Settlement (MOFS) dated September 1, 2025. This agreement is designed to address long-standing disputes related to shareholding and management rights in various listed and unlisted entities, including Kopran Limited.

Objectives of the Family Settlement

The primary objectives of the MOFS include:

• Resolving family disputes
• Settling inequalities in the partition of family businesses
• Preserving family property by avoiding litigation
• Maintaining the family's honor

Restructuring of Promoter Groups

As per the agreement, the promoters will be categorized into three distinct groups, each representing a branch of the Somani family:

1. The branch led by Mr. Susheel G. Somani
2. The branch comprising the lineal descendants of Late Mr. Rajendra Somani, headed by Mr. Adarsh Somani
3. The branch led by Mr. Surendra Somani

Impact on Management Control

The MOFS is expected to have a significant impact on the management and control of Kopran Limited. Previously, control was exercised jointly by promoters across multiple family branches. Following this agreement, management control will be consolidated and vested solely with the promoters of a single family branch acting together.

Share Transfer and Promoter Classification

The agreement outlines plans for inter-se transfer and purchase of shares among the family branches. Additionally, promoters within each group will be deemed as persons acting in concert. However, the three groups will not be regarded as acting in concert with each other, and their respective rights, obligations, and liabilities will remain separate.

Implications for Shareholders and Investors

While this agreement primarily affects the promoter group, it could have implications for the company's strategic direction and governance. Shareholders and investors should note that this restructuring aims to streamline decision-making processes and potentially lead to more efficient management of the company.

The execution of this family settlement marks a significant milestone in Kopran's corporate journey, potentially paving the way for more focused growth strategies and streamlined operations in the future.

Kopran Limited , a pharmaceutical company, has set September 4, 2025, as the record date for its upcoming dividend payment, subject to shareholder approval. The announcement comes as part of the company's preparations for its Annual General Meeting (AGM) scheduled for September 11, 2025.

Key Details

• Record Date: September 4, 2025
• AGM Date: September 11, 2025

Dividend Payment and Approval Process

The dividend payment is contingent upon approval by the company's shareholders at the upcoming AGM. If approved, the dividend will be subject to tax deduction at source, as per applicable regulations.

Regulatory Compliance

Kopran Limited has made this announcement in compliance with Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has duly informed both the Bombay Stock Exchange (BSE) and the National Stock Exchange of India (NSE) about the record date and AGM details.

Company Information

Kopran Limited is headquartered at Parijat House, 1076, Dr. E. Moses Road, Worli, Mumbai - 400 018. The company's manufacturing facilities are located in Village Savroli, Taluka Khalapur, District Raigad - 410 202.

Investors and shareholders are advised to take note of the record date for dividend eligibility. The final decision on the dividend declaration will be made at the Annual General Meeting, where members will have the opportunity to vote on the proposal.

Shareholders and potential investors are encouraged to attend or follow the proceedings of the Annual General Meeting on September 11, 2025, for the final decision on the dividend payment and other important company matters.